“[...] the identification of ubiquitin-conjugating enzymes like UBE2J1 and the innovative deployment of PROTAC-type androgen receptor degraders are crucial in combating prostate cancer and overcoming therapeutic resistance.”
BUFFALO, NY- June 7 , 2024 – A new editorial paper was published in Oncoscience ( Volume 11 ) on May 6, 2024, entitled, “ Restoring our ubiquitination machinery to overcome resistance in cancer therapy .”
In this new editorial, researchers Xiaoling Li and Ping Mu from the University of Southwestern Medical Center discuss the ubiquitin-proteasome system (UPS), which is usually responsible for regulating protein degradation, important for cellular homeostasis, and crucial in cancer progression. Its ability to regulate the stability of proteins that drive cancer growth and survival indicates its potential as a therapeutic target.
Among the UPS components, ubiquitin-conjugating enzymes, such as ubiquitin-conjugating enzyme E2 J1 (UBE2J1), have emerged as key players in cancer dynamics, especially in prostate cancer (PCa) where therapy resistance is a significant challenge.
“In our recent study, through a comprehensive in vivo library screening [ 2 ], we have identified the role of UBE2J1 in PCa, particularly its involvement in the degradation of the androgen receptor (AR) [ 3 ].”
Continue reading: DOI: https://doi.org/10.18632/oncoscience.600
Correspondence to: Ping Mu
Email: ping.mu@utsouthwestern.edu
Keywords: androgen receptor, prostate cancer, antiandrogen resistance, UBE2J1, ubiquitination, protein degradation, PROTAC
About Oncoscience :
Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.
To learn more about Oncoscience , visit Oncoscience.us and connect with us on social media:
For media inquiries, please contact media@impactjournals.com .
Oncoscience Journal Office
6666 East Quaker Str., Suite 1D
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 4
###
Oncoscience
Commentary/editorial
People
Restoring our ubiquitination machinery to overcome resistance in cancer therapy
6-May-2024